Clinical review report : Eculizumab (Soliris) : Alexion Pharma Canada Corp. : indication: neuromyelitis optica spectrum disorder / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

Common drug review clinical review report.

Common drug review clinical review report

Language:

English

Subjects (All):

Systematic reviews (Medical research).

Physical Description:

1 online resource.

Place of Publication:

Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2020.

Summary:

The objective of this report was to perform a systematic review of the beneficial and harmful effects of eculizumab 10 mg/mL intravenous infusion for the treatment of neuromyelitis optica spectrum disorder in adult patients who are anti-aquaporin-4 antibody positive.

Contents:

Abbreviations

Executive Summary

Introduction

Stakeholder Engagement

Clinical Evidence

Conclusions

Disease Background

Standards of Therapy

Drug

Patient Group Input

Clinician Input

Systematic Review: Pivotal and Protocol Selected Studies

Findings From the Literature

Results

Other Relevant Evidence

Discussion

Summary of Available Evidence

Interpretation of Results

Appendix 1. Literature Search Strategy

Appendix 2. Excluded Studies

Appendix 3. Detailed Outcome Data

Appendix 4. Description and Appraisal of Outcome Measures

Appendix 5. Description and Analysis of the Aquaporin-4 Antibody Detection Tests in Patients With NMOSD

References.

Notes:

Description based on publisher supplied metadata and other sources.